GRP78 was differentially overexpressed in pediatric AML blasts, independently of the underlying mutation in all samples (TARGET: AML subgroup vs. CB CD34+ p < 0.05) (Fig. 1a). This evidence concerns the gene HSPA5 and acute myeloid leukemia.